Log in to search using one of your social media accounts:

 

Efficient control of leukaemia with treatment by dual immune-checkpoint blockade
(Luxembourg Institute of Health) Chronic lymphocytic leukaemia (CLL) is a haematological malignancy. When infiltrating tissues, CLL cells come in contact with healthy cells, including immune cells. Researchers from the Luxembourg Institute of Health (LIH) succeeded in characterising in depth the composition of immune cells and circulating cytokines of the CLL microenvironment in mouse models using mass cytometry. Based on this knowledge, they propose an immunotherapeutic strategy with two immune checkpoint inhibitors that efficiently blocks disease development in preclinical tests. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 17, 2018 Category: Cancer & Oncology Source Type: news

Cancer researchers receive more than $2 million to eradicate common form of leukemia
(Scripps Research Institute) The researchers will investigate how to design antibodies to deliver drugs to fight chronic lymphocytic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2018 Category: Cancer & Oncology Source Type: news

Pan-PI3K Inhibitor Voxtalisib Active in FL but Less So in CLL, DLBCL
In a phase II study, voxtalisib, which targets all four class I PI3Ks, had efficacy in FL but limited clinical effect in MCL, DLBCL, and CLL/SLL. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Hematologic Malignancies News Source Type: news

International CLL Group Updates Trials Guidelines
The International Workshop on Chronic Lymphocytic Leukemia has updated its 2008 consensus guidelines for design and conduct of CLL clinical trials. (Source: CancerNetwork)
Source: CancerNetwork - March 23, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia News Source Type: news

Starting With Ibrutinib May Help Some Leukemia Patients Achieve Complete Response Starting With Ibrutinib May Help Some Leukemia Patients Achieve Complete Response
In patients with chronic lymphocytic leukemia (CLL), initial therapy with ibrutinib is among the factors that increase the likelihood of a complete response, according to pooled data from two trials.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CLL Responds to Induction With RCC Regimen Plus Rituximab Maintenance
CLL patients responded well to induction with the RCC regimen cladribine, cyclophosphamide, and rituximab followed by maintenance rituximab. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Immuno Oncology Source Type: news

Single-Agent Ibrutinib Active at 5 Years in CLL, SLL
Single-agent ibrutinib resulted in sustained efficacy and durable responses in treatment-naive or relapsed/refractory CLL or SLL, 5-year results show. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Chronic Lymphocytic Leukemia Immuno Oncology News Source Type: news

Verastem Submits NDA to FDA for Duvelisib for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
BOSTON--(BUSINESS WIRE)--Feb. 7, 2018-- Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced it has submitted a New Drug Application (NDA) to the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 7, 2018 Category: Drugs & Pharmacology Source Type: news

Find me a cure
When Simon Cox was first diagnosed with Chronic Lymphocytic Leukaemia (CLL), he feared the worst. But now there are promising developments. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 6, 2018 Category: Consumer Health News Source Type: news

Rituximab Maintenance a'Relevant' Option in Elderly CLL Patients Rituximab Maintenance a'Relevant' Option in Elderly CLL Patients
Two-years of rituximab maintenance therapy can prolong remission in selected elderly patients with chronic lymphocytic leukemia (CLL) in first remission after an abbreviated front-line course of fludarabine, cyclophosphamide and rituximab (FCR), according to a study from France.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Researchers detect a loophole in chronic lymphocytic leukemia treatment
(Rockefeller University Press) A team of researchers in Italy and Austria has determined that a drug approved to treat chronic lymphocytic leukemia (CLL) may be less effective in a particular subset of patients. The study, which will be published Jan. 4 in the Journal of Experimental Medicine, reveals that ibrutinib has a diminished capacity to delocalize and kill tumor cells expressing an adhesive protein called CD49d, but combining ibrutinib treatment with drugs that block CD49d activation could prevent the tumor cells from sheltering in lymphoid organs. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 4, 2018 Category: International Medicine & Public Health Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Media News)
Source: Roche Media News - December 12, 2017 Category: Pharmaceuticals Source Type: news

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia
Roche today announced the first results from the pivotal phase III MURANO study evaluating Venclexta ™/Venclyxto™ (venetoclax) plus MabThera®/Rituxan® (rituximab) compared to bendamustine plus MabThera®/Rituxan® (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukaemia (CLL). The results showed that a fixed duration of treatment with Venclexta/Venclyxto plus MabThera/Rituxan significantly reduced the risk of disease progression or death (progression-free survival; PFS, as assessed by investigator) by 83% compared with BR (HR=0.17; 95% CI 0.11-0.25; p (Source: Roche Investor Update)
Source: Roche Investor Update - December 12, 2017 Category: Pharmaceuticals Source Type: news

Ibrutinib and Venetoclax: Potential Combination for r/r CLL Ibrutinib and Venetoclax: Potential Combination for r/r CLL
Ibrutinib and venetoclax are already approved for the treatment of chronic lymphocytic leukemia, but new data suggest that using them together could be an option.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia
(Dana-Farber Cancer Institute) Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2017 Category: Cancer & Oncology Source Type: news

People willing to trade treatment efficacy for reduced side effects in cancer therapies
(American Society of Hematology) When choosing their preferred treatment, people with chronic lymphocytic leukemia place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a study published online in Blood Advances, a Journal of the American Society of Hematology. The study also suggests that factoring out-of-pocket costs into this decision-making process may significantly influence a patient's choice of treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 21, 2017 Category: International Medicine & Public Health Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Media News)
Source: Roche Media News - September 18, 2017 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Roche announced today that the phase III MURANO study, which evaluated Venclexta ®/Venclyxto® (venetoclax) in combination with MabThera®/Rituxan® (rituximab) in people with relapsed or refractory chronic lymphocytic leukaemia (CLL), met its primary endpoint and showed a statistically significant improvement in the time people lived without their disease progressing (progress ion-free survival [PFS] as assessed by investigator) when treated with Venclexta/Venclyxto plus MabThera/Rituxan compared to bendamustine plus Mabthera/Rituxan. (Source: Roche Investor Update)
Source: Roche Investor Update - September 18, 2017 Category: Pharmaceuticals Source Type: news

Verastem improves progression-free survival in Phase III trial for CLL and SLL
US-based biopharmaceutical firm Verastem has reported positive top-line results from the Phase III DUO clinical trial of duvelisib to treat relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies
Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom ’s macroglobulinemia and ma… (Source: Drug Development Technology)
Source: Drug Development Technology - July 18, 2017 Category: Pharmaceuticals Source Type: news

Adding Ublituximab to Ibrutinib Improves Relapsed CLL Response Rates
Adding the novel CD20 inhibitor ublituximab to ibrutinib offered improved response rates and greater depth of response over ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 23, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: World Pharma News)
Source: World Pharma News - June 23, 2017 Category: Pharmaceuticals Tags: Featured Roche Business and Industry Source Type: news

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Roche today announced new data from multiple studies of Venclexta ®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. (Source: Roche Media News)
Source: Roche Media News - June 23, 2017 Category: Pharmaceuticals Source Type: news

Presentation confirms Venclexta/Venclyxto monotherapy benefit in certain patients with high-risk chronic lymphocytic leukaemia and its potential in other hard-to-treat blood cancers
Roche today announced new data from multiple studies of Venclexta ®/Venclyxto® (venetoclax), presented at the 22nd European Hematology Association (EHA) Annual Congress, 22-25 June, in Madrid. (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Media News)
Source: Roche Media News - June 23, 2017 Category: Pharmaceuticals Source Type: news

FDA approves Rituxan Hycela (rituximab and hyaluronidase human) for subcutaneous injection in certain blood cancers
Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan Hycela ™ (rituximab and hyaluronidase human) for subcutaneous (under the skin) injection, for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), and previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - June 23, 2017 Category: Pharmaceuticals Source Type: news

CAR T Cell/Ibrutinib Combination May Improve CLL Response Rates
Despite immune-related adverse events, concurrent ibrutinib and anti-CD19 CAR T-cell therapy may improve response rates in patients with chronic lymphocytic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Hematology Leukemia & Lymphoma News Source Type: news

Truxima (rituximab) for the Treatment of Cancer
ruxima ™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well… (Source: Drug Development Technology)
Source: Drug Development Technology - June 8, 2017 Category: Pharmaceuticals Source Type: news

Janssen reports positive follow-up data from Phase III trial of Imbruvica for CLL
Janssen-Cilag International (Janssen) has reported positive data from a four-year follow-up period of its Phase III RESONATE trial of Imbruvica (ibrutinib) to treat relapsed / refractory (R/R) chronic lymphocytic leukaemia (CLL) patients. (Source: Drug Development Technology)
Source: Drug Development Technology - June 6, 2017 Category: Pharmaceuticals Source Type: news

Data at ASCO Show Consistent Progression-Free Survival Benefit in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated with Ibrutinib, Including Those with High-Risk Disease, with Up to Four Years of Follow-Up
(Source: Johnson and Johnson)
Source: Johnson and Johnson - June 5, 2017 Category: Pharmaceuticals Source Type: news

New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment This release corresponds to abstract #7524 NORTH CHICAGO, Ill., June 5, 2017 -- (Healthcare Sales & Marketing Network) -- IMBR... Biopharmaceuticals, Oncology AbbVie, IMBRUVICA, ibrutinib, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 5, 2017 Category: Pharmaceuticals Source Type: news

Personalized cell therapy combination achieves complete remission in CLL patients
(University of Pennsylvania School of Medicine) Combining the kinase inhibitor ibrutinib with an investigational personalized cellular therapy known as CTL119 can lead to complete remission in patients with high-risk chronic lymphocytic leukemia (CLL), according to new research from the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center (ACC). The team will present the results from its pilot study of this combination therapy during the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract # 193355). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2017 Category: Cancer & Oncology Source Type: news

Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions
This review will highlight the survival impact that rituximab therapy has had on major lymphoid malignancies, such as diffuse large B-cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and mantle cell lymphoma. We will also discuss alternative anti-CD20 monoclonal antibodies. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2017 Category: Cancer & Oncology Authors: Jonathan W. Friedberg, MD, MMSc Patrick M. Reagan, MD Tags: Hematologic Malignancies Leukemia & Lymphoma Oncology Journal Review Article Source Type: news

New blood cancer study with'outstanding' results
Research reveals'transformative outcomes'for patients with chronic lymphocytic leukemia. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 27, 2017 Category: Science Source Type: news

'Outstanding' results announced from new blood cancer study
(University of Leicester) Research led by University of Leicester and University Hospitals of Leicester NHS Trust reveals 'transformative outcomes' for patients with chronic lymphocytic leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 27, 2017 Category: Cancer & Oncology Source Type: news

How Time Zones May Affect Cancer Risk
WASHINGTON — Where you live within your time zone could be associated with a slightly increased risk of developing certain cancers that have been linked to disruptions of the biological clock, a new study suggests. People’s biological clocks can become out of whack — which scientists call “circadian disruption” — if they work the night shift, for example. Such disruptions have been linked to an increased cancer risk in shift workers, said Dr. Neil Caporaso, an epidemiologist at the National Cancer Institute and the lead author of the study. But the disruptions that shift workers experien...
Source: Healthy Living - The Huffington Post - April 5, 2017 Category: Consumer Health News Source Type: news

MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
SAN DIEGO, April 3, 2017 -- (Healthcare Sales & Marketing Network) -- MEI Pharma, Inc. (MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced the appointment of Brian Drazba as Chief Financial Office... Biopharmaceuticals, Oncology, Personnel MEI Pharma, acute myeloid leukemia, chronic lymphocytic leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 3, 2017 Category: Pharmaceuticals Source Type: news

FDA advisory committee unanimously recommends approval of Roche ’s subcutaneous rituximab for certain blood cancers
Roche announced today that the U.S. Food and Drug Administration ’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously (11 to 0) that the benefit-risk of rituximab/hyaluronidase for subcutaneous (under the skin) injection was favourable for the treatment of certain blood cancers, which include: previously untreated follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL), relapsed or refractory low grade or follicular lymphoma, and previously untreated and relapsed or refractory chronic lymphocytic leukemia (CLL). (Source: Roche Investor Update)
Source: Roche Investor Update - March 30, 2017 Category: Pharmaceuticals Source Type: news

BeiGene begins dosing in Phase II trial of BGB-3111 for CLL / SLL treatment in China
BeiGene has begun dosing in a Phase II clinical trial of its investigational drug candidate BGB-3111 for the treatment of patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in China. (Source: Drug Development Technology)
Source: Drug Development Technology - March 13, 2017 Category: Pharmaceuticals Source Type: news

A 5-Question Quiz on Chronic Lymphocytic Leukemia
What conditions are associated with CLL development? What novel agent resulted in significantly better progression-free survival in all CLL settings? Test your knowledge in our latest quiz. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2017 Category: Cancer & Oncology Authors: Debra Hughes Tags: Quiz Source Type: news

Frontline CLL Therapy: Changes in Paradigm
Significant progress has been made in the treatment of chronic lymphocytic leukemia with the addition of options such as the tyrosine kinase inhibitor ibrutinib, the monoclonal antibody obinutuzumab, and the BCL2 inhibitor venetoclax. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2017 Category: Cancer & Oncology Authors: Kanti Rai, MD Tags: Hematologic Malignancies Conferences/ICHM 2017 Leukemia & Lymphoma Q Source Type: news

Mutations Tied to Ibrutinib Resistance in Leukemia Mutations Tied to Ibrutinib Resistance in Leukemia
In patients with chronic lymphocytic leukemia, mutations indicating acquired resistance to the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may help guide therapy, researchers say. (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 22, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Genetically engineered T-cells treat leukemia in babies
[Image courtesy of Caroline Davis2010, per Creative Commons 2.0 license]Researchers in London have successfully treated leukemia in two babies, in what they are touting as the world’s first treatment of cancer using genetically engineered immune cells from donors. Two British infants, who were 11 and 16 months old, were treated using Cellectis’ CAR T-cell product, UCART19, which is an allogeneic CAR T-cell product candidate for the treatment of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). They had gone through previous radiation treatments that failed before being treated with Cell...
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Biotech Research & Development immunotherapy leukemia Source Type: news

Reasons for Ibrutinib Discontinuation Linked With Length of CLL Survival
Patients with chronic lymphocytic leukemia who discontinue treatment with ibrutinib due to disease progression or transformation had significantly worse survival compared with patients who discontinued therapy because of intolerance. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Source Type: news

Chemotherapy vs Ibrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia
This video examines frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia, including considerations for when chemotherapy or ibrutinib might be more appropriate. (Source: CancerNetwork)
Source: CancerNetwork - February 8, 2017 Category: Cancer & Oncology Authors: Susan O ’Brien, MD Tags: Videos Hematologic Malignancies Source Type: news

Study links immune system genetic variants to development of leukaemia
A new study has found that people inheriting genetic variants affecting the function of their immune system are at risk of developing chronic lymphocytic leukaemia (CLL). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 7, 2017 Category: Pharmaceuticals Source Type: news

Venetoclax Plus Rituximab:'Unprecedented' Efficacy in CLL Venetoclax Plus Rituximab:'Unprecedented' Efficacy in CLL
A new chemo-free combination, venetoclax and rituximab, has shown complete response rates in half of patients with refractory or relapsed chronic lymphocytic leukemia (CLL).Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 24, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

3 things to know about 2016 drug approvals
In 2016, the U.S. Food and Drug Administration ’s (FDA) Center for Drug Evaluation and Research (CDER)approved 22 new medicines to treat a broad range of illnesses for patients in need. These much-needed new treatments include medicines for multiple sclerosis, chronic lymphocytic leukemia, ovarian and bladder cancer and the very rare spinal muscular atrophy (SMA). (Source: The Catalyst)
Source: The Catalyst - January 6, 2017 Category: Pharmaceuticals Tags: Medicines in Development PhRMA Fact Check FDA Modernization Source Type: news

Invasive Squamous Cell Carcinoma of the Scalp and Calvarium Invasive Squamous Cell Carcinoma of the Scalp and Calvarium
This report describes utilizing a multidisciplinary approach for calvarial reconstruction in a patient with chronic lymphocytic leukemia and invasive squamous cell carcinoma of the scalp.ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 5, 2017 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

New Cancer Drug Approvals From 2016
Chemotherapy is one of the most powerful tools we have to treat cancer, and research continues to find new chemotherapy drugs as well as new uses for existing ones. At the same time, newer types of drugs are continually being developed that work in different ways to attack cancer cells.They include targeted therapy, which aims to more precisely identify cancer cells while doing less damage to normal cells, and immunotherapy, which uses the body’s own immune system to help find and destroy cancer.Before any new drug can be sold in the United States, it has to go through an approval process by the Food and Drug Adminis...
Source: American Cancer Society :: News and Features - December 26, 2016 Category: Cancer & Oncology Tags: Advanced Cancer Source Type: news